Maze Therapeutics (NASDAQ:MAZE) Stock Gets Price Target Increase from Wedbush

Key Points

• Wedbush raised its price target on Maze Therapeutics from $48 to $49 and maintained an “outperform” rating, implying about 39.9% upside from the prior close.
• Analyst views are mixed, but the consensus rating is “Buy” with an average price target of $64.55; ratings include three Strong Buys, ten Buys, and one Sell.
• Maze reported a quarterly loss of $0.79 per share, slightly worse than analysts’ $0.78 loss estimate.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) had its price objective upped by research analysts at Wedbush from $48.00 to $49.00 in a report issued on Tuesday, Benzinga reports. The firm currently has an "outperform" rating on the stock. Wedbush's price target indicates a potential upside of 39.88% from the company's previous close.

A number of other equities research analysts have also recently commented on the company. HC Wainwright reissued a "buy" rating and set a $110.00 price target on shares of Maze Therapeutics in a report on Thursday, September 24th. Wall Street Zen lowered Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Canaccord Genuity Group started coverage on Maze Therapeutics in a research report on Monday, October 19th. They set a "buy" rating and a $75.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Monday, September 21st. Finally, Citigroup began coverage on Maze Therapeutics in a research note on Wednesday, September 23rd. They issued a "buy" rating and a $50.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $64.55.

Maze Therapeutics Stock Up 0.3%

Shares of MAZE stock traded up $0.12 during mid-day trading on Tuesday, hitting $35.03. The company's stock had a trading volume of 16,521 shares, compared to its average volume of 669,144. Maze Therapeutics has a 52-week low of $21.95 and a 52-week high of $53.65. The business has a 50-day moving average price of $27.94 and a 200 day moving average price of $31.72. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -13.92 and a beta of 2.04. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.01). Research analysts predict that Maze Therapeutics will post -2.70 EPS for the current fiscal year.

Insider Transactions at Maze Therapeutics

In related news, CMO Harold Bernstein sold 16,141 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $26.93, for a total transaction of $434,677.13. Following the completion of the sale, the chief marketing officer owned 16,141 shares of the company's stock, valued at $434,677.13. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the firm's stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $32.07, for a total value of $240,525.00. Following the completion of the sale, the insider directly owned 32,316 shares of the company's stock, valued at $1,036,374.12. The trade was a 18.84% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 192,991 shares of company stock valued at $5,187,559 over the last 90 days. 5.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Bessemer Group Inc. increased its position in shares of Maze Therapeutics by 3.0% during the 3rd quarter. Bessemer Group Inc. now owns 496,253 shares of the company's stock worth $13,488,000 after purchasing an additional 14,463 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in Maze Therapeutics in the third quarter valued at about $1,519,000. Alps Advisors Inc. lifted its position in Maze Therapeutics by 31.5% in the third quarter. Alps Advisors Inc. now owns 73,574 shares of the company's stock valued at $2,000,000 after buying an additional 17,604 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Maze Therapeutics in the third quarter valued at about $77,000. Finally, Profund Advisors LLC boosted its stake in Maze Therapeutics by 410.5% during the third quarter. Profund Advisors LLC now owns 56,281 shares of the company's stock worth $1,530,000 after buying an additional 45,256 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets.

The company's Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.

Founded in 2018, Maze is headquartered in South San Francisco, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.